Quick Take
10x Genomics (TXG) went public in September 2019, selling 10 million shares of stock at $39.00, raising $390 million in gross proceeds, excluding underwriter shares.
The firm provides a range of equipment and software for genetic research purposes.
TXG has strong prospects in a white hot industry, but I can’t pin down whether the rebounded stock is a bargain or overvalued.
My outlook is Neutral based on valuation uncertainty.
Company
10x Genomics was founded in 2012 to develop and commercialize instruments, consumables and software for preparation for genetic sequencing.
Management is